FDA Approves Bristol-Myers, AstraZeneca Diabetes Drug

Law360, Washington (January 8, 2014, 4:05 PM EST) -- The U.S. Food and Drug Administration on Wednesday approved a Bristol-Myers Squibb Co. and AstraZeneca Pharmaceuticals LP drug designed to treat Type 2 diabetes, about one year after rejecting the same drug due to its potential link to bladder cancer.

The agency said in a news release that it had approved Farxiga, known generically as dapagliflozin, which improves glycemic control with diet and exercise for adults with Type 2 diabetes.

“Controlling blood sugar levels is very important in the overall treatment and care of diabetes, and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.